Biomedical Engineering Reference
In-Depth Information
98. Osterberg F, Aqvist J (2005) Exploring blocker binding to a homology model of the open
hERG K+ channel using docking and molecular dynamics methods. FEBS Lett 579:
2939-2944
99. Farid R, Day T, Friesner RA et al (2006) New insights about HERG blockade obtained from
protein modeling, potential energy mapping, and docking studies. Bioorg Med Chem 14:
3160-3173
100. Micheli F, Bonanomi G, Blaney FE et al (2007) 1,2,4-triazol-3-yl-thiopropyl-tetrahydroben-
zazepines: a series of potent and selective dopamine D(3) receptor antagonists. J Med Chem
50:5076-5089
101. Armstrong CM (1969) Inactivation of the potassium conductance and related phenomena
caused by quaternary ammonium ion injection in squid axons. J Gen Physiol 54:553-575
102. Thai KM, Windisch A, Stork D et al (2010) The hERG potassium channel and drug trapping:
insight from docking studies with propafenone derivatives. ChemMedChem 5:436-442
103. Fernandez D, Ghanta A, Kauffman GW et al (2004) Physicochemical features of the HERG
channel drug binding site. J Biol Chem 279:10120-10127
104. Karczewski J, Wang J, Kane SA et al (2009) Analogs of MK-499 are differentially affected
by a mutation in the S6 domain of the hERG K+ channel. Biochem Pharmacol 77:1602-1611
105. Perry M, Stansfeld PJ, Leaney J et al (2006) Drug binding interactions in the inner cavity of
HERG channels: molecular insights from structure-activity relationships of clofilium and
ibutilide analogs. Mol Pharmacol 69:509-519
106. Milnes JT, Witchel HJ, Leaney JL et al (2006) hERG K+ channel blockade by the antipsy-
chotic drug thioridazine: an obligatory role for the S6 helix residue F656. Biochem Biophys
Res Commun 351:273-280
107. Kiesecker C, Alter M, Kathofer S et al (2006) Atypical tetracyclic antidepressant maprotiline
is an antagonist at cardiac hERG potassium channels. Naunyn Schmiedebergs Arch
Pharmacol 373:212-220
108. Scherer D, von Lowenstern K, Zitron E et al (2008) Inhibition of cardiac hERG potassium
channels by tetracyclic antidepressant mianserin. Naunyn Schmiedebergs Arch Pharmacol 378:
73-83
109. Milnes JT, Crociani O, Arcangeli A et al (2003) Blockade of HERG potassium currents by
fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139:
887-898
110. Ridley JM, Milnes JT, Witchel HJ et al (2004) High affinity HERG K(+) channel blockade
by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652
and F656. Biochem Biophys Res Commun 325:883-891
111. Dougherty DA, Lester HA, Nowak MW (2006) US Patent US20060084102
112. Siebrands CC, Friederich P (2007) Structural requirements of human ether-a-go-go-related
gene channels for block by bupivacaine. Anesthesiology 106:523-531
113. Myokai T, Ryu S, Shimizu H et al (2008) Topological mapping of the asymmetric drug
binding to the human ether-a-go-go-related gene product (HERG) potassium channel by use
of tandem dimers. Mol Pharmacol 73:1643-1651
114. Imai YN, Ryu S, Oiki S (2009) Docking model of drug binding to the human ether-a-go-go
potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
J Med Chem 52:1630-1638
115. Price DA, Armour D, de Groot M et al (2006) Overcoming HERG affinity in the discovery of
the CCR5 antagonist maraviroc. Bioorg Med Chem Lett 16:4633-4637
116. Dinges J, Albert DH, Arnold LD et al (2007) 1,4-Dihydroindeno[1,2-c]pyrazoles with
acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors
with low affinity for the hERG ion channel. J Med Chem 50:2011-2029
117. Levoin N, Calmels T, Poupardin-Olivier O et al (2008) Refined docking as a valuable tool
for lead optimization: application to histamine H3 receptor antagonists. Arch Pharm
(Weinheim) 341:610-623
